The ongoing training of Zimmer Biomet's team and exhibition at AANS are essential steps to drive adoption of these novel technologies among neurosurgeons who typically require substantial evidence and education before adopting new surgical tools. Recent Company Highlights Management Commentary "The second quarter of fiscal 2025 was highlighted by our significant operational progress with our commercial OneRF ® Ablation System technology platform, which is increasingly being validated as a versatile and scalable platform across multiple applications," said Dave Rosa, CEO of NeuroOne. "Not only did we continue to have clinical success with patients who are remaining seizure free after being treated with our system, but we also successfully filed our 510(k) submission to the FDA for the OneRF ® Trigeminal Nerve Ablation System to treat facial pain well ahead of schedule.